Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction.
chronic nodular prurigo
itch
patient-reported outcome
pruritus
therapy
nodular prurigo
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
17 Feb 2021
17 Feb 2021
Historique:
pubmed:
16
12
2020
medline:
24
6
2021
entrez:
15
12
2020
Statut:
epublish
Résumé
Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.
Identifiants
pubmed: 33320272
doi: 10.2340/00015555-3726
pmc: PMC9366694
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00403Références
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2224-2229
pubmed: 29869425
Acta Derm Venereol. 2019 Apr 1;99(5):469-506
pubmed: 30931482
JAMA Dermatol. 2019 Jan 1;155(1):121-122
pubmed: 30427989
J Dtsch Dermatol Ges. 2008 Nov;6(11):941-6
pubmed: 18445069
Acta Derm Venereol. 2018 Jan 12;98(1):38-43
pubmed: 28929169
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):437-440
pubmed: 29055135
Clin Exp Dermatol. 2014 Jun;39(4):468-73
pubmed: 24825138
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2373-2383
pubmed: 32078192
Hautarzt. 2004 Dec;55(12):1130-6
pubmed: 15517116
J Eur Acad Dermatol Venereol. 2011 Jul;25(7):799-803
pubmed: 20946583
Acta Derm Venereol. 2018 Feb 7;98(2):173-179
pubmed: 29135018
J Eur Acad Dermatol Venereol. 2019 Aug;33(8):e303-e304
pubmed: 30893496
J Dtsch Dermatol Ges. 2017 Aug;15(8):860-873
pubmed: 28763608
Dermatology. 2013;227(4):353-60
pubmed: 24281309
J Dermatol. 2007 Apr;34(4):237-42
pubmed: 17352720
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):157-162
pubmed: 29923228
J Am Acad Dermatol. 1999 Oct;41(4):533-9
pubmed: 10495371
Br J Dermatol. 2010 Oct;163(4):823-31
pubmed: 20491772
Dermatology. 2011;223(2):107-12
pubmed: 21952556
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1823-1828
pubmed: 27027584
Br J Dermatol. 2009 Nov;161(5):1143-8
pubmed: 19857211
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e106-e107
pubmed: 27505149
Acta Derm Venereol. 2011 May;91(3):344-5
pubmed: 21279302
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1059-1065
pubmed: 28857299
J Am Acad Dermatol. 2018 Jun;78(6):1209-1211
pubmed: 29438756
Acta Derm Venereol. 2007;87(4):291-4
pubmed: 17598029
J Clin Pharm Ther. 2013 Feb;38(1):16-8
pubmed: 23013514
J Am Acad Dermatol. 2020 Feb;82(2):460-468
pubmed: 31310842
Acta Derm Venereol. 2019 Sep 1;99(10):905-906
pubmed: 31233177
JAMA Dermatol. 2019 Jan 1;155(1):118-120
pubmed: 30427994
N Engl J Med. 2020 Feb 20;382(8):706-716
pubmed: 32074418